Search
Lyell Immunopharma Inc
LYELAdd to Watchlist
10.120USD
-0.410-3.89%
Close 09-24 16:00（ET）
236.10MMarket Cap
LossP/E TTM
Lyell Immunopharma Inc (LYEL) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Lyell Immunopharma Inc in the past month.
Buy
1 Strong Buy
5 Buy
0 Hold
1 Sell
0 Strong Sell
Target Price
37.875USD+259.69%
LYEL Analyst Recommendation Trends
In the current month, LYEL has received 5 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. LYEL average Analyst price target in the last month is 37.875.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
0
0
0
0
0
5
4
4
3
2
2
2
1
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
7
6
6
4
3
3
3
3
LYEL Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, LYEL EPS is projected to reach -2.077 in FY2026Q3, following reported EPS of -1.916 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-2.23
-2.37
-2.02
-2.08
-2.15
Actual
-6.86
-1.10
-1.92
--
--
Surprise
-207.39%
+53.32%
+5.05%
--
--
FAQs
What is Lyell Immunopharma Inc's expected revenue for the next quarter?
Lyell Immunopharma Inc's expected revenue is 2.33K.
What is Lyell Immunopharma Inc's price target?
Analysts forecast that Lyell Immunopharma Inc's price target is USD 37.88, with the highest forecast at USD 49.00 and the lowest forecast at USD 12.00.
How have Lyell Immunopharma IncLYEL's recent earnings per share performed?
The market expectation was USD -1.92, while Lyell Immunopharma IncLYEL's earnings per share (EPS) for the previous quarter was USD -1.10. EPS for the next quarter is expected at USD -2.08.
What is the analyst rating for Lyell Immunopharma Inc?
Based on the ratings of Lyell Immunopharma Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.